Stoney I know you’re rich! You found SNAP at $8.
GBA Presents: House of Gummy-!
- Thread starter stonedinvestor
- Start date
WTF!---- These guys gave away 30% of the prize for what!!! 25 cent move!!!
Arrrrrrrrrrrrrrg! Sell this later today! Punk move. Showes how hard it is to borrow from banks.
EUenCore Energy Corp.
$4.260.20(+4.80%)9:42 AM 12/06/23-->
NYSE |$USD |Realtime
He's not talking to us today. And it was moi who called the perfect bottom on SNAP when it held $9.50 the day the NAZ crashed.
Verve director acquires $18M in company stock
Ok this is one of those they did a secondary but they got it off at $10 and a big buyer obviously was a director-- not the CEO.
I like this still $18 M is a big buy but in general these buys tied to secondaries can be seen as propping up the stk but that's usually 1 mil or 2... $10 is a commitment.
What wets the appetite is a recent sell off due to two deaths in trials---
Verve Therapeutics, Inc. (VERV) 30% on sale>
NasdaqGS - NasdaqGS Real Time Price.
12.22+0.65(+5.57%)<---------------------- Go Long/ Give it a try.
As of 09:50AM EST. Market open.
Gene editing and heart attacks
Verve is trying to build cutting-edge, gene-editing tools to help people deal with cardiovascular disease. Specifically, it hopes to commercialize its Verve-101 tool to edit human genes in people with naturally high LDL cholesterol (the bad cholesterol), which is correlated with heart disease. There are an estimated 3 million people in the United States and Europe affected by this condition, which indicates a potentially huge market for Verve if they can get this treatment commercialized.
This week, the company released some updated data for investors regarding a trial it is doing with the Verve-101 tool in humans. The market seems to be reacting to some concerning news with the 10 people Verve has trialed, as two of the patients died from heart attacks after receiving the treatment. Seeing this headline, the market reacted swiftly with investors likely concerned over the efficacy of this early-stage technology.
However, if we look under the hood, these heart attacks, from a research perspective, may not be as bad as they seem. Verve is purposefully looking for patients with extreme cardiovascular conditions, meaning they were already highly likely to have a heart attack before taking the drug. On a positive note, the trial indicates a 55% reduction in LDL levels for the patients, which is a huge improvement from current cholesterol-reduction methods.
Ok this is one of those they did a secondary but they got it off at $10 and a big buyer obviously was a director-- not the CEO.
I like this still $18 M is a big buy but in general these buys tied to secondaries can be seen as propping up the stk but that's usually 1 mil or 2... $10 is a commitment.
What wets the appetite is a recent sell off due to two deaths in trials---
Verve Therapeutics, Inc. (VERV) 30% on sale>
NasdaqGS - NasdaqGS Real Time Price.
12.22+0.65(+5.57%)<---------------------- Go Long/ Give it a try.
As of 09:50AM EST. Market open.
Gene editing and heart attacks
Verve is trying to build cutting-edge, gene-editing tools to help people deal with cardiovascular disease. Specifically, it hopes to commercialize its Verve-101 tool to edit human genes in people with naturally high LDL cholesterol (the bad cholesterol), which is correlated with heart disease. There are an estimated 3 million people in the United States and Europe affected by this condition, which indicates a potentially huge market for Verve if they can get this treatment commercialized.
This week, the company released some updated data for investors regarding a trial it is doing with the Verve-101 tool in humans. The market seems to be reacting to some concerning news with the 10 people Verve has trialed, as two of the patients died from heart attacks after receiving the treatment. Seeing this headline, the market reacted swiftly with investors likely concerned over the efficacy of this early-stage technology.
However, if we look under the hood, these heart attacks, from a research perspective, may not be as bad as they seem. Verve is purposefully looking for patients with extreme cardiovascular conditions, meaning they were already highly likely to have a heart attack before taking the drug. On a positive note, the trial indicates a 55% reduction in LDL levels for the patients, which is a huge improvement from current cholesterol-reduction methods.
STOCK OF THE WEEK UP $10!!! THIS IS OUR 15TH STOCK OF THE WEEK WINNER!!!!!
MASI TAKING OFF!
Masimo Corporation (MASI)
NasdaqGS - NasdaqGS Real Time Price.
103.44+$2.03 <-----------
As of 09:57AM EST.
Day 2 of the Cramer Correction.
I'm going to hit the gummy store early & the Green Market //
SPX S&P 500 Index
4,577.3822.49(+0.49%)<---
8:12 AM 11/29/23
CFD Derived Realtime
DAY 8 OF THE CRAMER CORRECTION & I AM SLIGHTLY WORRIED NOW THAT OUR END OF YEAR S&P TARGET 5,550 WILL BE EXCEEDED.
Sorry! I thought he liked it too.